The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.
[3 + 2] Cycloaddition of azides with arynes formed<i>via</i>C–H deprotonation of aryl sulfonium salts
作者:Xing-Wei Gu、Yan-Hua Zhao、Xiao-Feng Wu
DOI:10.1039/d3gc02052e
日期:——
Herein, we developed a new methodology of using aryl sulfonium salts as the aryne precursor for [3 + 2] cycloaddition reactions with azides. The reaction using readily available arenes as the feedstock features excellent atom economy, environmental friendliness and high functional group tolerance. Moreover, due to the excellent performance of the gram-scale reaction, deuterium labeling result and derivatization